Translating TRAIL-receptor targeting agents to the clinic

被引：66
|
作者：
den Hollander, Martha W. [1 ]
Gietema, Jourik A. [1 ]
de Jong, Steven [1 ]
Walenkamp, Annemiek M. E. [1 ]
Reyners, Anna K. L. [1 ]
Oldenhuis, Corina N. A. M. [1 ]
de Vries, Elisabeth G. E. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
来源：
CANCER LETTERS | 2013年 / 332卷 / 02期
关键词：
TRAIL; Clinical studies; Biomarkers; APOPTOSIS-INDUCING LIGAND; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; PHASE-I; FUSION PROTEIN; TUMOR-GROWTH; MAPATUMUMAB; COMBINATION; TRIAL; LEXATUMUMAB;
D O I：
10.1016/j.canlet.2012.04.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：194 / 201
页数：8
相关论文
共 50 条
  • [1] Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma
    Sug Hyung Lee
    Min Sun Shin
    Hong Sug Kim
    Hun Kyung Lee
    Won Sang Park
    Su Young Kim
    Jong Heun Lee
    Seo Young Han
    Jik Young Park
    Ro Ra Oh
    Chang Suk Kang
    Kyung Mee Kim
    Ja June Jang
    Suk Woo Nam
    Jung Young Lee
    Nam Jin Yoo
    [J]. Oncogene, 2001, 20 : 399 - 403
  • [2] Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma
    Lee, SH
    Shin, MS
    Kim, HS
    Lee, HK
    Park, WS
    Kim, SY
    Lee, JH
    Han, SY
    Park, JY
    Oh, RR
    Kang, CS
    Kim, KM
    Jang, JJ
    Nam, SW
    Lee, JY
    Yoo, NJ
    [J]. ONCOGENE, 2001, 20 (03) : 399 - 403
  • [3] Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease
    Brost, Sylvia
    Koschny, Ronald
    Sykora, Jaromir
    Stremmel, Wolfgang
    Lasitschka, Felix
    Walczak, Henning
    Ganten, Tom M.
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (01) : 43 - 50
  • [4] Targeting Trail Towards the Clinic
    Mahalingam, Devalingam
    Oldenhuis, Corina N. A. M.
    Szegezdi, Eva
    Giles, Francis J.
    de Vries, Elisabeth G. E.
    de Jong, Steven
    Nawrocki, Steffan T.
    [J]. CURRENT DRUG TARGETS, 2011, 12 (14) : 2079 - 2090
  • [5] Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
    Sarhan, Dhifaf
    D'Arcy, Padraig
    Lundqvist, Andreas
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (10) : 18557 - 18573
  • [6] TRAIL-receptor 2 protein expression in normal and tumor tissues
    Halpern, Wendy
    Lincoln, Clint
    Roach, Charlotte
    Sharifi, Amir
    Askaa, Jon
    Welcher, Rosanne
    Klein-Szanto, Andres
    Cohen, Roger
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 22 - 23
  • [7] Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
    Krishna Moorthy, Nivetha
    Seifert, Oliver
    Eisler, Stephan
    Weirich, Sara
    Kontermann, Roland E.
    Rehm, Markus
    Fullstone, Gavin
    [J]. MOLECULES, 2021, 26 (24):
  • [8] TRAIL-receptor 2—a novel negative regulator of p53
    Anna Willms
    Hella Schupp
    Michelle Poelker
    Alshaimaa Adawy
    Jan Frederik Debus
    Torsten Hartwig
    Tim Krichel
    Jürgen Fritsch
    Steven Singh
    Henning Walczak
    Silvia von Karstedt
    Heiner Schäfer
    Anna Trauzold
    [J]. Cell Death & Disease, 12
  • [9] TRAIL (APO2L) and TRAIL-receptor expression in relation to survival of patients with glioblastoma multiforme
    Kuijlen, JMA
    Mooij, JJA
    Hollema, H
    Hoving, EW
    van der Graaf, WTA
    den Dunnen, WFA
    [J]. NEURO-ONCOLOGY, 2005, 7 (03) : 371 - 371
  • [10] Targeting TRAIL Death Receptors: TRAIL from the Lab to the Clinic
    De Jong, S.
    De Vries, E. G. E.
    [J]. KLINISCHE PADIATRIE, 2011, 223 (01): : 47 - 47
12345